logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Merrimack Pharmaceuticals, Inc.


USPTO Granted Patents = 52



Trademarks = 4

Forward Citations = 444

Loading Chart...
Loading Chart...

81 inventors (with patents filed for the assignee):

goldMedal Ulrik Bjerl Nielsen (17 out of 24 patents)

silverMedal Birgit Schoeberl (11 out of 16 patents)

bronzeMedal Michael Feldhaus (10 out of 29 patents)

4.  Neeraj Kohli (10 out of 12 patents)

5.  Alexey Alexandrovich Lugovskoy (9 out of 50 patents)

6.  Jonathan Basil Fitzgerald (9 out of 19 patents)

7.  Thomas Joseph Wickham (9 out of 15 patents)

8.  Dmitri B Kirpotin (8 out of 45 patents)

9.  Daryl C Drummond (7 out of 36 patents)

10.  Jeffrey David Kearns (7 out of 7 patents)

11.  Victor Mandla Moyo (7 out of 43 patents)

12.  Eric Krauland (6 out of 20 patents)

13.  Brian Harms (6 out of 11 patents)

14.  Raghida Bukhalid (6 out of 6 patents)

15.  Bart S Hendriks (5 out of 7 patents)


Core Competencies:
Anti-TNFR2 Antibodies
Ataxia Telangiectasia and Rad3-Related Protein
Biomarker Profiles
Nucleic Acid Delivery
Bi-Specific Fusion Proteins
Non-Invasive Imaging
EGFR Antibodies
Combination Therapy
Liposomal Drug Delivery
ERBB3 Inhibitors
Cardiotoxicity Prevention
Tumor Treatment Methods

52 patents:

1. 12435151 - Anti-TNFR2 antibodies and uses thereof (2025-10-07),
2. 10570119 - Inhibiting ataxia telangiectasia and Rad3-related protein (ATR) (2020-02-25),
3. 10273304 - Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies (2019-04-30),
4. 10184006 - Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors (2019-01-22),
5. 10087464 - Compositions and methods for delivering nucleic acid to a cell (2018-10-02),
6. 10072299 - Antibodies against epidermal growth factor receptor (EGFR) and uses thereof (2018-09-11),
7. 9982060 - Bi-specific fusion proteins (2018-05-29),
8. 9968694 - Compositions and methods for non-invasive imaging (2018-05-15),
9. 9938346 - Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies (2018-04-10),
10. 9920131 - Dosage and administration of anti-EGFR therapeutics (2018-03-20),
11. 9913901 - Combination therapy for treating HER2-positive cancers (2018-03-13),
12. 9902999 - Antibodies against epidermal growth factor receptor (EGFR) and uses thereof (2018-02-27),
13. 9885087 - Antibodies against epidermal growth factor receptor (EGFR) and uses thereof (2018-02-06),
14. 9718892 - Method of treating myocardial infarction by administering a bi-specific fusion protein (2017-08-01),
15. 9688761 - Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies (2017-06-27),
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for the treatment of cancer. They are dedicated to advancing science and transforming patient care by targeting novel biological pathways. Merrimack Pharmaceuticals is committed to bringing hope to patients and improving their quality of life.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

52 Patents

#41 in Cambridge, MA

#374 in Massachusetts

#6,542 in US

#13,162 in the World

...
Cambridge, MA, United States of America

Merrimack Pharmaceuticals, Inc.

Forward Citations = 444

81 inventors:

goldMedal Ulrik Bjerl Nielsen (17 out of 24 patents)

silverMedal Birgit Schoeberl (11 out of 16 patents)

bronzeMedal Michael Feldhaus (10 out of 29 patents)

4.  Neeraj Kohli (10 out of 12 patents)

5.  Alexey Alexandrovich Lugovskoy (9 out of 50 patents)

Please report any incorrect information to support@idiyas.com
Loading…